Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer

G. Thomas Budd, MD
Published Online: Tuesday, June 25, 2013
G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses the background and results of the S0221 trial in breast cancer.

Previously, Budd says, researchers analyzed two dose-dense regimens and found that treatment with doxorubicin-cyclophosphamide followed by paclitaxel given every two weeks was more effective than the same regimen with all drugs given every three weeks.

Another trial looked at the same regimen given weekly and compared it to treatment every three weeks. In this analysis, weekly treatment was better than treatment every three weeks.

In the S0221 trial, researchers compared these two schools of thought, Budd says. The trial showed that in terms of efficacy, these two regimens produced similar outcomes, but the side effects differed.

Read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting

Online CME Activities
Free CME from PER
Update From ASCO: Advances in Immunotherapy for Non–Small Cell Lung Cancer and Melanoma
Updates in Supportive Care From ASCO 2014
Community Practice Connections: Personalization of NSCLC Therapy: Novel Breakthroughs in Patient Care
Cancer Summaries and Commentaries: Update from Chicago – Advanced Gastrointestinal Cancers
More Reading
Publications
$auto_registration$